Company intelligence / Profile preview

Actelion Pharmaceuticals Ltd

Allschwil, Basel-Landschaft, Switzerlandactelion.com ↗

Ownership: Public · ATLN
Employees: ~2600
Development stage: Other

Overview

Actelion became a global leader in pulmonary arterial hypertension with several approved therapies including Tracleer, Opsumit, Veletri, Ventavis, and Uptravi. The company also developed Zavesca for lysosomal storage disorders. Its clinical pipeline was spun out into Idorsia at the time of Johnson & Johnson’s acquisition in June 2017. At acquisition by J&J ($30B), it had a robust commercial portfolio and late-stage assets.[2][8]

Therapeutic areas: Rare DiseasesCardiovascularNeurology
Modalities: Small molecules (e.g., bosentan, macitentan, selexipag)Prostacyclin analogs and receptor agonists[3]
Industry: Biotech

Partnerships

Roche collaboration on S1P1 modulators [6]GSK collaboration on Almorexant [6]Merck collaboration in renin inhibition [6]

Beyond the preview

Go deeper on Actelion Pharmaceuticals Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actelion Pharmaceuticals Ltd.